WASHINGTON (dpa-AFX) - AbbVie, Inc. (ABBV) announced Tuesday that a new
weight-based oral solution RINVOQ LQ (upadacitinib) is now available as an
option for pediatric patients two years of age and older with active
polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic
arthritis (PsA), provided they have had an inadequate response or intolerance to
one or more tumor necrosis factor (TNF) blockers.

RINVOQ (upadacitinib) is already indicated in the U.S. for the treatment of
these pediatric patients. It is now approved for eight indications across
immune-mediated inflammatory diseases.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX